Drug intelligence / Profile preview

LAU-OralCare

Development stage: Preclinical
Lead developer: Vectans Pharma
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical, Buccal

Overview

LAU-OralCare is a therapeutic candidate being developed by Vectans Pharma for the treatment of various oral cavity conditions. It utilizes the proprietary Lauriad technology, which is a muco-adhesive buccal delivery platform. This technology consists of a small tablet designed to adhere to the oral mucosa (typically the upper gum), where it provides a sustained and controlled release of the active pharmaceutical ingredient directly to the affected area. By focusing delivery within the oral cavity, the Lauriad system aims to achieve high local drug concentrations and improved efficacy while minimizing systemic exposure and associated side effects.

Beyond the preview

Go deeper on LAU-OralCare.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAU-OralCare.

Explore the full profile